# EDGAR Filing Document

**Accession Number:** 0001859007
**File Stem:** 0001641172-25-022236
**Filing Date:** 2025-8
**Character Count:** 2650
**Document Hash:** c476854cebbd04041c0343ee8641cebb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-022236.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001641172-25-022236

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZyVersa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001859007
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 862685744
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2200 N. COMMERCE PARKWAY
- **STREET 2:** SUITE 208
- **CITY:** WESTON
- **STATE:** FL
- **ZIP:** 33326
- **BUSINESS PHONE:** 908-370-5102

**MAIL ADDRESS:**
- **STREET 1:** 2200 N. COMMERCE PARKWAY
- **STREET 2:** SUITE 208
- **CITY:** WESTON
- **STATE:** FL
- **ZIP:** 33326

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Larkspur Health Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210426

**ZyVersa Therapeutics, Inc.**

**2200 N. Commerce Parkway, Suite 208**

**Weston, Florida 33326**

**(754) 231-1688**

August 5, 2025

**<u>VIA EDGAR SUBMISSION</u>**

U.S. Securities and Exchange Commission<br> Division of Corporation Finance<br> 100 F Street, N.E.<br> Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | ZyVersa Therapeutics, Inc. |
|  | Registration Statement on Form S-1 |
|  | SEC File No. 333-288470 |
|  | Request for Acceleration |

---

To whom it may concern:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-288470) (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective at 4:30 P.M., eastern time, on August 6, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Thompson Hine LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Thompson Hine LLP, by calling Faith L. Charles at (212) 908-3905.

Please feel free to direct any questions or comments concerning this request to Faith L. Charles of Thompson Hine LLP at (212) 908-3905.

---

| | |
|:---|:---|
| **ZYVERSA THERAPEUTICS, INC.** | **ZYVERSA THERAPEUTICS, INC.** |
| By: | */s/ Stephen C. Glover* |
| Name: | Stephen C. Glover |
| Title: | Chief Executive Officer |

---

Cc: Faith L. Charles, Thompson Hine LLP